Welcome to NGC. Skip directly to: Search Box, Navigation, Content.


Brief Summary

GUIDELINE TITLE

Consensus criteria for the diagnosis of multifocal motor neuropathy.

BIBLIOGRAPHIC SOURCE(S)

GUIDELINE STATUS

This is the current release of the guideline.

BRIEF SUMMARY CONTENT

 
RECOMMENDATIONS
 EVIDENCE SUPPORTING THE RECOMMENDATIONS
 IDENTIFYING INFORMATION AND AVAILABILITY
 DISCLAIMER

 Go to the Complete Summary

RECOMMENDATIONS

MAJOR RECOMMENDATIONS

Definition

Multifocal motor neuropathy is a disease of lower motor neurons in adults that produces asymmetrical muscle weakness, often in association with fasciculations and cramping.

The diagnosis of multifocal motor neuropathy is a difficult one. Until further research clarifies the issue, the criteria for definitive and probable multifocal neuropathy listed below are proposed to serve as a guide for diagnosing this disease.

Criteria for the Diagnosis of Multifocal Motor Neuropathy

Criteria for Definite Multifocal Motor Neuropathy

  1. Weakness without objective sensory loss in the distribution of two or more of the following nerves: median, ulnar, radial, peroneal, and tibial. During the early stages of symptomatic weakness, the historical or physical finding of diffuse, symmetric weakness excludes multifocal motor neuropathy.
  2. Definite conduction block (for criteria for partial conduction block, see Table 1 in the original guideline document) is present in two or more nerves outside of common entrapment sites (median nerve at wrist; ulnar nerve at elbow or wrist; peroneal nerve at fibular head).
  3. Normal sensory nerve conduction velocity across the same segments with demonstrated motor conduction block.
  4. Normal results for sensory nerve conduction studies on all tested nerves, with a minimum of three nerves tested.
  5. The absence of each of the following upper motor neuron signs: spastic tone, clonus, extensor plantar response, and pseudobulbar palsy.

Criteria for Probable Multifocal Motor Neuropathy

  1. Weakness without objective sensory loss in the distribution of two or more of the following nerves: median, ulnar, radial, peroneal, and tibial. During the initial weeks of symptomatic weakness, the presence of diffuse, symmetric weakness excludes multifocal motor neuropathy.
  2. The presence of either:
    1. Probable conduction block in two or more motor nerve segments that are not common entrapment sites or
    2. Definite conduction block in one motor nerve segment and probable conduction block in a different motor nerve segment, neither of which segments are common entrapment sites.
  3. Normal sensory nerve conduction velocity across the same segments with demonstrated motor conduction block, when this segment is technically feasible for study (that is, this is not required for segments proximal to axilla or popliteal fossa).
  4. Normal results for sensory nerve conduction studies on all tested nerves, with a minimum of three nerves tested.
  5. The absence of each of the following upper motor neuron signs: spastic tone, clonus, extensor plantar response, and pseudobulbar palsy.

CLINICAL ALGORITHM(S)

None provided

EVIDENCE SUPPORTING THE RECOMMENDATIONS

TYPE OF EVIDENCE SUPPORTING THE RECOMMENDATIONS

The type of supporting evidence is not specifically stated for each recommendation.

IDENTIFYING INFORMATION AND AVAILABILITY

BIBLIOGRAPHIC SOURCE(S)

ADAPTATION

Not applicable: Guideline was not adapted from another source.

DATE RELEASED

2003 Jan

GUIDELINE DEVELOPER(S)

American Association of Neuromuscular and Electrodiagnostic Medicine - Medical Specialty Society

SOURCE(S) OF FUNDING

American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM)

GUIDELINE COMMITTEE

Not stated

COMPOSITION OF GROUP THAT AUTHORED THE GUIDELINE

Primary Authors Richard K. Olney, MD; Richard A. Lewis, MD; Timothy O. Putnam, MD; Joseph V. Campellone, Jr., MD

FINANCIAL DISCLOSURES/CONFLICTS OF INTEREST

Not stated

GUIDELINE STATUS

This is the current release of the guideline.

GUIDELINE AVAILABILITY

AVAILABILITY OF COMPANION DOCUMENTS

None available

PATIENT RESOURCES

None available

NGC STATUS

This NGC summary was completed by ECRI on December 1, 2003.

COPYRIGHT STATEMENT

DISCLAIMER

NGC DISCLAIMER

The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.

All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.

Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at http://www.guideline.gov/about/inclusion.aspx .

NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.

Readers with questions regarding guideline content are directed to contact the guideline developer.


 

 

   
DHHS Logo